$EVR

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

NEW HAVEN, Conn., Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Nasdaq: IVVD ) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.

Original reporting
GlobeNewswire · Invivyd
Published Nov 25, 2025, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 25, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference — source image
Decision brief

The 30-second read

$EVRNeutralMed
01

Why it matters

Management's participation could serve as a platform to highlight recent progress or strategic plans, potentially influencing investor sentiment.

02

Market read

The event holds moderate relevance for IVVD investors, with potential for short-term price movements based on management disclosures.

03

What to watch

Market may have already priced in the upcoming conference participation; any impact depends on the content and reception of management's discussion.

Relevance 6/10Timing: Immediate, as the event is scheduled for December 2, 2025.

Background

Invivyd is a biotech company involved in developing therapies, with upcoming participation in a major healthcare conference.

Company-level read

Ticker impact

$EVRNeutralMedium confidence
Context

Low relevance due to minimal direct impact on the healthcare sector and limited influence on Invivyd's stock.

Expected impact

No significant price movement expected in EVR or IVVD based on this news.

Evidence & confidence

The news is about a conference participation with no new product announcements or financial disclosures. The sentiment is neutral, and relevance scores are low, indicating limited impact.

$IVVDBullishHigh confidence
Context

High relevance due to positive sentiment and direct association with the event, potentially influencing investor perception.

Expected impact

Potential short-term upward movement (~3-5%) in IVVD stock following the event, contingent on management's disclosures and market perception.

Evidence & confidence

Corporate events with management participation often serve as catalysts for investor interest, especially if accompanied by positive disclosures or strategic updates.

Market effects

Possible positive sentiment in the biotech and healthcare sectors due to active corporate engagement.

Limited regional impact; event is localized to Miami, FL.

Minimal direct global market impact; regional event with company-specific relevance.

Counterpoint

The event may be a routine corporate engagement with no material new information, thus unlikely to impact stock prices significantly.

Key entities

  • Invivyd, Inc.

    A biotechnology company focused on developing therapies for infectious diseases.

  • Evercore Healthcare Conference

    A platform for healthcare companies to present and discuss their strategies and developments.

Related articles

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

$IVVDMedAI 9/10

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

$IVVDMedAI 8/10

Invivyd Reports VYD2311 Meets Primary Safety Endpoints In Phase 3 Trial

Invivyd (IVVD) reported that its COVID-19 monoclonal antibody VYD2311 met primary safety endpoints in the Phase 3 LIBERTY study, showing favorable safety and tolerability compared to an mRNA vaccine. The study enrolled 210 healthy adults, with 56.5% of VYD2311 recipients experiencing adverse events versus 91.4% for the vaccine. The company plans to use the data to support a BLA submission to the FDA. IVVD stock closed at $0.95, up 1.69%, and is trading at $0.99 in pre-market.

$AAPLMed

Evercore Resets Apple Stock Price Target for 2026

Evercore ISI raised its Apple AAPL price target to $380, citing strong consumer interest in premium iPhone 18 models and other Apple products. The firm's survey showed 53% of respondents plan to buy iPhone 18 Pro or Pro Max, up from historical averages. Apple shares are near record highs, trading around $337.